Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vigil Neuroscience, Inc. VIGL
$9.06
-$0.06 (-0.71%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
328260978.00000000
-
week52high
16.77
-
week52low
2.18
-
Revenue
0
-
P/E TTM
-11
-
Beta
0.00000000
-
EPS
-2.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 04:00
Описание компании
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Equal-Weight | Equal-Weight | 17 мая 2022 г. |
| Stifel | Buy | 01 февр 2022 г. | |
| Morgan Stanley | Equal-Weight | 01 февр 2022 г. | |
| Jefferies | Buy | 01 февр 2022 г. | |
| Wedbush | Outperform | 16 сент 2022 г. | |
| HC Wainwright & Co. | Buy | 29 авг 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 14 ноя 2022 г. |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Papapetropoulos Spyros | D | 149604 | 300 | 18 ноя 2022 г. |
| Papapetropoulos Spyros | D | 4000 | 300 | 18 ноя 2022 г. |
| Papapetropoulos Spyros | A | 4300 | 300 | 18 ноя 2022 г. |
| Bruhn Suzanne Louise | A | 24310 | 24310 | 27 июл 2022 г. |
| Thistle Mary | A | 12155 | 12155 | 09 июн 2022 г. |
| Blanchard Cheryl R | A | 12155 | 12155 | 09 июн 2022 г. |
| Vitorovic Stefan | A | 12155 | 12155 | 09 июн 2022 г. |
| Booth Bruce | A | 12155 | 12155 | 09 июн 2022 г. |
| Koenig Gerhard | A | 12155 | 12155 | 09 июн 2022 г. |
| Thorp Clay | A | 1556030 | 14893 | 17 мая 2022 г. |
Новостная лента
Vigil Neuroscience to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, at 8:15 a.m. PT / 11:15 a.m. ET.
Vigil Neuroscience to Present at Upcoming Investor Conferences
GlobeNewsWire
07 ноя 2022 г. в 07:00
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at three upcoming investor conferences. Details are as follows:
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
24/7 Wall Street
24 окт 2022 г. в 21:21
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
Wall Street Analysts Predict a 121% Upside in Vigil Neuroscience, Inc. (VIGL): Here's What You Should Know
Zacks Investment Research
14 сент 2022 г. в 11:13
The consensus price target hints at a 121.3% upside potential for Vigil Neuroscience, Inc. (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vigil Neuroscience to Present at 2022 Morgan Stanley Global Healthcare Conference
GlobeNewsWire
01 сент 2022 г. в 07:00
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of the management team will participate in a fireside chat at the 2022 Morgan Stanley Global Healthcare Conference on Monday, September 12, 2022, at 4:50 p.m. ET.